A retrospective review of 4,721 human immunodeficiency virus (HIV)-infected patients, followed at St. Luke's Roosevelt Hospital Center, New York City, was conducted from January 1, 2005 to December 31, 2009. HIV-Hepatitis B virus (HBV) co-infection rate was 218/4,721, 4.6%. Among co-infected patients, 19 patients (19/218, 8.7%) died; 13 patients (13/19, 68.4%) died from non-acquired immune deficiency syndrome (AIDS) defining including 2 patients with liver failure. More non-survivors (5 patients, 5/19, 26.3%) had liver cirrhosis than those who survived (74 patients, 74/199, 37.2%; \( P = 0.002 \)). There were more patients with positive HBV e antigen (HBeAg) among non-survivors, (12 patients, 12/19, 63.2%) than among survivors (74 patients, 74/199, 37.2%; \( P = 0.047 \)). HIV-HBV co-infection is associated with increased overall mortality. Therefore, use of dual active antiretrovirals, particularly, tenofovir (TDF) based regimen for optimal suppression of HIV-HBV and immune restoration with prevention of high risk behaviors may contribute to improved outcomes.

**Key Words:** HIV; Hepatitis B Virus; Mortality
mL) was 3.00. Median ALT was 39 U/L. Radiographic evidence for liver cirrhosis was noted in 13 patients (13/218, 6.0%). Undetectable HBV viral load was seen in 83 patients (83/218, 38.1%). HBV genotype was done in 19 patients and majority of genotype was A (11/19, 57.9%) and G (7/19, 36.8%) with lamivudine resistance in 5 patients. Positive HBeAg was noted in 86 patients (86/218, 39.4%). Loss of HBsAg was noted in 11 patients (11/218, 5.0%) and seroconversion of positive HBsAb occurred in 7 patients. There were 183 patients (183/218, 83.9%) who received anti-HBV treatment with or without part of highly active antiretroviral therapy (HAART) for HIV treatment. The combination treatment of tenofovir (TDF)/emtricitabine (FTC) was the most commonly used regimen and overall TDF based regimen was observed in majority of patients on anti-HBV treatment (149/183, 81.4%). Of interest, among 83 patients who had undetectable HBV DNA viral load, 63 patients (63/83, 75.9%) were on TDF based anti-HBV treatment regimen. Also 7 patients (7/11, 64%) of those who lost HBsAg were noted to be on TDF based regimen.

Table 1. Comparison of survivors and non-survivors in HIV-Hepatitis B virus (HBV) co-infected patients

| Parameters | Survivors n (199/218, 91.3%) | Non-survivors n (19/218, 8.7%) | P value |
|------------|-------------------------------|-----------------------------|---------|
| Age (yr) (median, IQR) | 46 (41-51) | 47 (40-55) | 0.494 |
| Sex | | | |
| Male (%) | 156 (78.4) | 17 (89.5) | 0.376 |
| Female (%) | 43 (21.6) | 2 (10.5) | |
| Race | | | |
| White (%) | 33 (16.6) | 2 (10.5) | 0.745 |
| Black (%) | 124 (62.3) | 15 (78.9) | 0.212 |
| Hispanic (%) | 40 (20.1) | 2 (10.5) | 0.541 |
| Asian (%) | 2 (1.0) | 0 (0.0) | 1.000 |
| HIV risk factors | | | |
| Hetero (%) | 82 (41.2) | 7 (36.8) | 0.810 |
| MSM (%) | 91 (45.7) | 8 (42.1) | 0.814 |
| IDU (%) | 20 (10.1) | 4 (21.1) | 0.140 |
| Other (%) | 6 (3.0) | 0 (0.0) | 1.000 |
| Presence of HCV (%) | 30 (15.1) | 4 (21.1) | 0.508 |
| ALT (median, IQR) | 36 (23-61) | 50 (39-63) | 0.208 |
| Presence of cirrhosis (%) | 8 (4.0) | 5 (26.3) | 0.002 |
| Positive HBV e antigen (%) | 74 (37.2) | 12 (63.2) | 0.047 |
| Undetectable HBV viral load (%) | 79 (39.7) | 4 (21.1) | 0.140 |
| CD4 count (median, IQR) | 288 (125-463) | 215 (94-395) | 0.285 |
| HIV viral load (Log10 median, IQR) | 2.92 (1.87-4.61) | 4.08 (2.60-4.80) | 0.135 |
| Treatment | | | |
| No treatment (%) | 32 (16.1) | 3 (15.8) | 1.000 |
| TDF-based treatment (%) | 138 (69.3) | 11 (57.9) | 0.311 |
| Non-TDF-based treatment (%) | 29 (14.6) | 5 (26.3) | 0.188 |

IQR, interquartile range; MSM, male sex male; IDU, intravenous drug use; HCV, hepatitis C virus; ALT, alanine transaminase; TDF, tenofovir.
significantly, however, non-AIDS mortality in HIV-infected patients increased (8, 9). Results of the present study correspond with the results of earlier studies which reported decreasing trend of AIDS-related deaths. Death rate in our cohort of HIV-HBV co-infected patients was 3.1 deaths/100 person-years, which was higher than that of recent study (1.3 deaths/100 persons-years in 2004) conducted for overall HIV-infected patients in the multiple United States cities (8), suggesting vulnerability of HIV-HBV co-infected patients to all-cause mortality as evidenced from a recent meta-analysis (10).

The increased overall mortality rate in HIV-HBV co-infected patients has been attributed to liver disease (11). And our results of liver cirrhosis presence and HBeAg reactivity as significant factors for all-cause mortality for both AIDS-related and non-AIDS-related mortality including liver-related mortality would support this assumption from the previous study to some extent. However, an important finding in our study was that majority of mortality was due to non-liver related mortality. A recent meta-analysis (10) showed that the summary estimate of HIV-HBV co-infection studies performed after 1997 implied a lower risk of death due to liver-related causes in the HAART era.

Currently, liver-related mortality may have diminished in HIV-HBV co-infected patients with increased use of agents with dual activity against HIV and HBV, particularly TDF, which has been associated with highly suppressive HBV serological and/or virological outcomes with decrease in liver fibrosis score (12) without significant development of resistance (13). Also our data demonstrated that majority of patients who achieved loss of HBsAg and undetectable HBV viral load were on TDF based regimen with low incidence of overall liver cirrhosis and liver-related mortality, which further supports the use of TDF in the HIV-HBV co-infected patients.

The exact mechanisms for excess mortality risk in HIV-HBV co-infected patients is not completely understood, especially in the age of potent combinations of dual active antiretrovirals such as TDF/FTC. There are several possible reasons. First, both direct effects from chronic HBV infection manifested as liver cirrhosis/failure/carcinoma and indirect effects from chronic HBV infection on the host’s immune system manifested as weak and narrowly focused immune response with T cell dysfunction (14, 15) need to be considered. Particularly, our study demonstrated HBeAg as a significant factor associated with all-cause mortality. Presence of HBeAg was associated with downregulation of Toll-like receptor 2 expression on hepatocytes and monocytes leading to decreased cytokine expression (16), suggesting a significant interaction between HBV infection with positive HBeAg and innate immune response. In addition, further immunomodulatory effects from HIV infection can lead to increased susceptibility to other diseases. Second, high-risk behaviors associated with HIV-HBV co-infection may place these patients at an increased risk for mortality (14, 17), as our study showed that MSM and IDU were noted in the 45.4%, 11.0% of the patients, respectively, with including mortality of suicide and drug over dose.

Our study has limitations, however, mostly stemming from its small sample size and its retrospective nature. Although factors such as older age, low CD4 T cell count, detectable HIV viral load were shown to be associated with mortality in HIV-infected patients with compensated liver cirrhosis in the HAART era (18), our study did not show significant association between these factors and overall mortality in HIV-HBV co-infected patients. This might reflect one of limitations based on small sample size due to retrospective nature, not true absence of association. Nonetheless, our cohort of patients might well represent current urban HIV-HBV co-infected patients in the United States or other developed country with access to HIV care. Therefore, this study results should be of assistance to manage HIV-HBV co-infected patients.

In summary, HIV-HBV co-infection continues to be substantial clinical challenges in urban HIV clinic in the United States. HIV-HBV co-infection is associated with increased overall mortality. Therefore, use of dual active antiretrovirals, particularly, TDF based HAART regimen for optimal suppression of HIV-HBV and immune restoration with prevention of high risk behaviors may contribute to improved outcomes in the management of HIV-HBV co-infected patients.

REFERENCES
1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-9.
2. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23: 125-36.
3. Thio CL, Seagar EC, Skalsky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-6.
4. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-10.
5. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65-70.
6. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldsvold-Pico C, Carey W, Brown BS Jr, Luketic VA, Terrault N, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125: 444-51.
7. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26: 123-30.
8. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:
9. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.

10. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, Kalapothaki V, Hatzakis A. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48: 1763-71.

11. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D’Acunto K, Phair J, Thio CL. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23: 1881-9.

12. Boyd A, Lasnier E, Molina JM, Lascoux-Combe C, Bonnard P, Mailhes P, Wendum D, Meynard JL, Girard PM, Lacombe K. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther 2010; 15: 963-74.

13. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaier HL, Prins JM, Pas SD, Schutten M, Hoepelman AI, Richter C, Mulder JW, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139: 1934-41.

14. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol 2005; 34: 132-7.

15. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90.

16. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards B, Rodgers S, Kurtovic J, Chang J, Lewin S, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007; 45: 102-10.

17. Jain MK. Mortality in patients coinfected with hepatitis B virus and HIV: could antiretroviral therapy make a difference? Clin Infect Dis 2009; 48: 1772-4.

18. Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano I, Martin-Carbonero L, Labarga P, Barreiro P, Soriano V. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS 2010; 24: 745-53.